Related Experiment Video
Updated: Jul 10, 2026

Stabilized Window for Intravital Imaging of the Murine Pancreas
Published on: October 6, 2023
Dipeptidyl peptidase IV (DPP IV/CD26) is a cell-surface plasminogen receptor
Mario Gonzalez-Gronow1, Steven Kaczowka, Govind Gawdi
1Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA. Gonza002@mc.duke.edu
Abstract:
Binding of plasminogen (Pg) to cell-surface receptors colocalized with plasminogen activators promotes Pg activation and enables cells to utilize the proteolytic activity of plasmin (Pm). Proteolysis by Pm is necessary in several physiological and pathological processes requiring extracellular matrix degradation including cell migration, tumor cell invasion and metastasis. The binding of Pg to cell-surface receptors is regulated by two major structural features: L-lysine binding sites (LBS) and negatively charged sialic acid residues located on its carbohydrate chains. Pg uses its LBS to bind to a wide spectrum of cell-surface receptors whereas binding through its sialic acid residues is limited only to receptor proteins containing cationic pockets or lectin-like modules. In this review, we discuss both mechanisms, including the identification of DPP IV as a Pg receptor and the possible physiological role of Pg/Pm in complex with DPP IV and adenosine deaminase (ADA) and /or the Na+/H+ exchanger isoform NHE-3 in prostate cancer.
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Cytoskeletal Linker Proteins - Plakins
IP3/DAG Signaling Pathway
Insulin: The Receptor and Signaling Pathways

